	US 12,109,303 B2
	Orally dissolving antimicrobial film compositions and methods of their use
Manoj P. Jadhav, Hillsborough, NJ (US); Mangal Shailesh Nagarsenkar, Maharashtra (IN); Supriya Shrihari Shidhaye, Maharashtra (IN); and Shivali Hargovind Tank, Maharashtra (IN)
Assigned to ISHA THERAPEUTICS LLC, Hillsborough, NJ (US)
Filed by ISHA Therapeutics LLC, Hillsborough, NJ (US)
Filed on Apr. 18, 2023, as Appl. No. 18/302,720.
Application 18/302,720 is a continuation of application No. PCT/US2023/065861, filed on Apr. 17, 2023.
Claims priority of provisional application 63/331,956, filed on Apr. 18, 2022.
Prior Publication US 2023/0330012 A1, Oct. 19, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 31/7048 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61P 31/10 (2006.01)

CPC A61K 9/006 (2013.01) [A61K 31/7048 (2013.01); A61K 47/18 (2013.01); A61K 47/186 (2013.01); A61K 47/22 (2013.01); A61P 31/10 (2018.01)]

20 Claims

1. An antifungal ionic liquid composition of amphotericin B comprising (1) amphotericin B; (2) a complexing agent component comprising a first complexing agent and a second complexing agent, wherein the first complexing agent and the second complexing agent form a single ionic complex with the amphotericin B; (3) a solvent component comprising an amount of at least one solvent compound and at least one solvent acidifying agent that when combined with the solvent compound forms an acidified solvent, wherein the at least one solvent acidifying agent further (a) represents one of the first or the second complexing agents forming the ionic complex with the amphotericin B and (b) detectably modulates the pH of the composition; and (4) a solubilizing component comprising an amount of at least one solubilizing agent which detectably or significantly increases the solubilization of the amphotericin B, wherein each of the solvent acidifying agent and the solvent compound are present in the composition in an amount representing between about 0.5% w/v and about 5% w/v of the composition.